STING agonists, including cGAMP analogs, show promise in cancer immunotherapy and as vaccine adjuvants, while small-molecule inhibitors of cGAS or STING, such as covalent STING inhibitors, demonstrate potential for treating autoimmune diseases (e.g., AGS) and other chronic inflammatory disorders. Here, STING1 is linked to Aicardi-Goutieres syndrome.